A study reportedby Zhang et al. found that while the ASK1 inhibitor exhibited no effecton MKN45 cells, the PHORCs, composed of ASK1 inhibitor and a phosphataseactivator, could reduce p-ASK1T838 levels both in vitro and in vivo and demonstrated anticanceractivity on MKN45 cancer cell line and MKN45 xenograft mouse model,suggesting the therapeutic potential of PHORCs as anticancer agents.119 Identifying MGs between PTM enzymes and targetproteins can potentially be a strategy to bypass ligand discoveryfor allosteric sites on the writer/eraser. This evidence concerns the gene MAP3K5 and cancer.